Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...

Australian pharmaceutical companies retreated in morning trade after shares in US pharma giant Eli Lilly dived 14% overnight, due disappointing data on its new oral weight loss pill.